Control of Pneumocystis Infections

Burke BA , Good RA . Pneumocystis carinii infection. Medicine 1973;52(1):23–51.

Frenkel JK , Bartlett MS , Smith JW . RNA homology and the reclassification of Pneumocystis. Diagn Microbiol Infect Dis 1990;13(1):1–2.

McKenzie R , Travis WD , Dolan SA , Pittaluqa S , Feuerstein IM , Shelhamer J , et al. The causes of death in patients with human immunodeficiency virus infection: a clinical and pathological study with emphasis on the role of pulmonary diseases. Medicine 1991;70(5):326–343.

Travis WD . Pathological features. In: Pneumocystis carinii pneumonia. Walzer PD , editor. New York: Marcel Dekker Inc, 1994:155–180.

Dohn MN , Frame PT . Clinical manifestations in adults. In: Pneumocystis carinii pneumonia. Walzer PD , editor. New York: Marcel Dekker Inc, 1994:331–359.

Hughes WT . Clinical manifestations in children. In: Pneumocystis carinii pneumonia. Walzer PD , editor. New York: Marcel Dekker Inc, 1994:319–331.

Masur H. Prevention and treatment of pneumocystis pneumonia. N Engl J Med 1992;327(26):1853–1860. See the published erratum in N Engl J Med 1993;328(15):1136.

Schneider MM , Hoepelman AI , Schattenkerk JK , Nielsen TL , van der Graaf Y , Frissen PH , et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency syndrome. N Engl J Med 1992;327(26):1836–1841.

Hardy WD , Feinberg J , Finkelstein DM , Power ME , He W , Kaczka C , et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;327(26):1842–1848.

Western KA , Perera DR , Schultz MG . Pentamidine isethionate in the treatment of Pneumocystis carinii pneumonia. Ann Int Med 1970;73(5):695–702.

Kovacs JA , Allegra CJ , Beaver J , Boarman D , Lewis M , Parrillo JE , et al. Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: potential for screening therapeutic agents. J Infect Dis 1989;160(2):312–320.

Schweitzer BI , Dicker AP , Bertino JR. Dihydrofolate reductase as a therapeutic target. FASEB J 1990;4(8):2441–2452.

Walker RE , Masur H. Current regimens of therapy and prophylaxis. In: Pneumocystis carinii pneumonia. Walzer PD , editor. New York: Marcel Dekker Inc, 1994:439–466.

Post C , Fakouhi T , Dutz W , Bandarizadeh B , Kohout E. Prophylaxis of epidemic infantile pneumocystosis with a 20:1 sulfadoxine and pyrimethamine combination. Curr Ther Res Clin Exp 1971;13(5):273–279.

Hughes WT , Feldman S , Sanyal SK . Treatment of Pneumocystis carinii pneumonitis with trimethoprim-sulfamethoxazole. Can Med Assoc 1975;112(13, Special No.):47–50.

Queener SF . New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii. J Med Chem 1995;38(4):4739–4759.

Volpe F , Ballantine SP , Delves CJ . The multifunctional folic acid synthesis fas gene of Pneumocystis carinii encodes dihydroneopterin aldolase, hydroxymethyldihydropterin pyrophosphokinase and dihydropteroate synthase. Eur J Biochem 1993;216(2):449–458.

Medina I , Mills J , Leoung G , Hopewell PC , Lee B , Modin G , et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990;323(12):776–782.

Hughes WT , Smith BL , Jacobus DP . Successful treatment and prevention of murine Pneumocystis carinii pneumonitis with 4,4'-sulfonylbisformanilide. Antimicrob Agents Chemother 1986;29(3):509–510.

Then RL , Hartman PG , Kompis I , Santi D. Selective inhibition of dihydrofolate reductase from problem human pathogens. In: Ayling JE , Nair MG , Baugh CM , editors. Chemistry and biology of pteridines and folates. New York: Plenum Press, 1993:533–536.

Allegra CJ , Kovacs JA , Drake JC , Swan JC , Chabner BA , Masur H. Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. J Exp Med 1987;165(3):926–931.

Kovacs JA , Allegra CJ , Swan JC , Drake JC , Parrillo JE , Chabner BA , Masur H. Potent anti-Pneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate. Antimicrob Agents Chemother 1988;32(4):430–433.

Bailly C , Donkor IO , Gentle D , Thornalley M , Waring MJ . Sequence-selective binding to DNA of cis-and trans-butamidine analogues of the anti-Pneumocystis carinii pneumonia drug pentamidine. Mol Pharmacol 1994;46:313–322.

Tidwell RR , Jones SK , Geratz JD , Ohemeng KA , Bell CA , Berger BJ , Hall JE . Development of pentamidine analogues as new agents for the treatment of Pneumocystis carinii pneumonia. Ann NY Acad Sci 1990;616:421–441.

Brun-Pascaud M , Fay M , Zhong M , Bauchet J , Dux-Guyot A , Pocidalo JJ . Use of fluoroquinolones for prophylaxis of murine Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 1992;36:470–472.

Queener SF , Bartlett MS , Richardson JD , Durkin MM , Jay MA , Smith JW . Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo. Antimicrob Agents Chemother 1988;32(6):807–813.

Hughes WT . Hydroxynaphthoquinones. In: Walzer PD , editor. Pneumocystis carinii pneumonia. New York: Marcel Dekker Inc, 1993:603–613.

Hughes W , Leoung G , Kramer F , Bozzette A , Safrin S , Frame P , Cluneck N , et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993;328(21):1521–1527.

Yeates CI , Cheesman NJ , Follenfant MJ , Frend AJ , Pudney M. The synthesis and comparative pharmacokinetics of 81C91 -a water soluble oral prodrug of atovaquone (abstract). Abstr ICAAC 1993;33:189 (abstract 381).